NZOZ LECZNICA MAK-MED s.c.
- Address
- lock Available on a paid plan
Eye Diseases
The site expands its inflammatory disease expertise to ocular health, exploring new treatments for ocular inflammation and related eye conditions.
- Investigation of biologic agents for uveitis
- Evaluation of systemic immunomodulator safety on eye health
- Pilot study of topical therapy for inflammatory eye disease
NZOZ LECZNICA MAK-MED s.c. integrates eye‑focused research within its broader autoimmune portfolio.
Immune System Diseases
Trials concentrate on systemic autoimmunity, including systemic lupus erythematosus and Sjögren’s disease, to test innovative targeted therapies and improve disease control.
- Novel JAK inhibitor study for systemic lupus erythematosus
- Combination biologic approach in Sjögren’s disease
- Safety profiling of immune modulators across autoimmune disorders
The research team at NZOZ LECZNICA MAK-MED s.c. aims to broaden therapeutic options for patients with immune‑mediated diseases.
Musculoskeletal Diseases
A robust program addresses inflammatory joint disorders such as rheumatoid arthritis and psoriatic arthritis, as well as degenerative knee disease, evaluating efficacy of new biologics and oral agents.
- Efficacy assessment of new biologics in rheumatoid arthritis
- Biosimilar versus reference product comparison for joint disease
- Pain‑reduction outcomes in participants with knee osteoarthritis
- Long‑term safety of anti‑TNF therapy in psoriatic arthritis
NZOZ LECZNICA MAK-MED s.c. leverages its expertise to advance treatment options for musculoskeletal conditions.
Nutritional and Metabolic Diseases
Research focuses on weight management and metabolic health, particularly in individuals with obesity and comorbid joint disease, to determine how weight loss influences symptom severity.
- Weight‑loss intervention trial using obesity as primary endpoint
- Diet‑exercise adjunct study on knee pain in obese participants
- Metabolic profiling of subjects receiving novel oral agents
The centre’s metabolic studies complement its broader autoimmune and musculoskeletal research agenda.
Skin and Connective Tissue Diseases
Ongoing investigations target chronic skin disorders such as plaque psoriasis, testing new biologics to reduce lesions and improve patient quality of life.
- Phase III evaluation of oral therapy for plaque psoriasis
- Biosimilar comparison for psoriasis severity scoring
- Long‑term safety of subcutaneous treatment in severe skin disease
- Efficacy of IL‑23 inhibition in moderate to severe psoriasis
NZOZ LECZNICA MAK-MED s.c. strives to bring innovative skin‑focused therapies to market.
Stomatognathic Diseases
Emerging projects explore how systemic immunomodulators affect oral health, including salivary gland function and mucosal healing.
- Observational study of salivary gland function under immune modulators
- Assessment of oral mucosal recovery with biologic therapy
- Safety monitoring of dental health during systemic trial participation
The site’s expanding portfolio now incorporates stomatognathic research to address comprehensive patient wellbeing.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 15 of 25 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Dr Reddy's Laboratories Limited1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Dr Reddy's Laboratories Limited2trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in NZOZ LECZNICA MAK-MED s.c.
lock Showing 1 of 14 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis | MoonLake Immunotherapeutics AG | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 25 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Methotrexate | 4 | Unknown | 2024-02-08 | 2024-12-17 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.